Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer.

Labidi-Galy SI, Olivier T, Rodrigues M, Ferraioli D, Derbel O, Bodmer A, Petignat P, Rak B, Chopin N, Tredan O, Heudel PE, Stuckelberger S, Meeus P, Meraldi P, Viassolo V, Ayme A, Chappuis PO, Stern MH, Houdayer C, Stoppa-Lyonnet D, Buisson A, Golmard L, Bonadona V, Ray-Coquard I.

Clin Cancer Res. 2018 Jan 15;24(2):326-333. doi: 10.1158/1078-0432.CCR-17-2136. Epub 2017 Oct 30.

PMID:
29084914
2.

High grade serous ovarian carcinomas originate in the fallopian tube.

Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, Bhattacharya R, Novak M, Jones S, Phallen J, Hruban CA, Hirsch MS, Lin DI, Schwartz L, Maire CL, Tille JC, Bowden M, Ayhan A, Wood LD, Scharpf RB, Kurman R, Wang TL, Shih IM, Karchin R, Drapkin R, Velculescu VE.

Nat Commun. 2017 Oct 23;8(1):1093. doi: 10.1038/s41467-017-00962-1.

3.

Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer.

Ballestrero A, Bedognetti D, Ferraioli D, Franceschelli P, Labidi-Galy SI, Leo E, Murai J, Pommier Y, Tsantoulis P, Vellone VG, Zoppoli G.

J Transl Med. 2017 Oct 2;15(1):199. doi: 10.1186/s12967-017-1296-3.

4.

Clinical Development of Anti-mitotic Drugs in Cancer.

Olziersky AM, Labidi-Galy SI.

Adv Exp Med Biol. 2017;1002:125-152. doi: 10.1007/978-3-319-57127-0_6. Review.

PMID:
28600785
5.

Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response.

De Picciotto N, Cacheux W, Roth A, Chappuis PO, Labidi-Galy SI.

Crit Rev Oncol Hematol. 2016 May;101:50-9. doi: 10.1016/j.critrevonc.2016.02.014. Epub 2016 Feb 27. Review.

PMID:
26964893
6.

Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors.

Labidi-Galy SI, Clauss A, Ng V, Duraisamy S, Elias KM, Piao HY, Bilal E, Davidowitz RA, Lu Y, Badalian-Very G, Györffy B, Kang UB, Ficarro S, Ganesan S, Mills GB, Marto JA, Drapkin R.

Oncogene. 2015 Jan 15;34(3):373-83. doi: 10.1038/onc.2013.562. Epub 2014 Jan 27.

7.

Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer.

Williams KA, Labidi-Galy SI, Terry KL, Vitonis AF, Welch WR, Goodman A, Cramer DW.

Gynecol Oncol. 2014 Mar;132(3):542-50. doi: 10.1016/j.ygyno.2014.01.026. Epub 2014 Jan 23.

8.

Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms.

Elias KM, Labidi-Galy SI, Vitonis AF, Hornick JL, Doyle LA, Hirsch MS, Cramer DW, Drapkin R.

Gynecol Oncol. 2014 Feb;132(2):328-33. doi: 10.1016/j.ygyno.2013.12.011. Epub 2013 Dec 14.

9.

Breast cancer-derived transforming growth factor-β and tumor necrosis factor-α compromise interferon-α production by tumor-associated plasmacytoid dendritic cells.

Sisirak V, Vey N, Goutagny N, Renaudineau S, Malfroy M, Thys S, Treilleux I, Labidi-Galy SI, Bachelot T, Dezutter-Dambuyant C, Ménétrier-Caux C, Blay JY, Caux C, Bendriss-Vermare N.

Int J Cancer. 2013 Aug 1;133(3):771-8. doi: 10.1002/ijc.28072. Epub 2013 Mar 8.

10.

Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression.

Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, Renaudineau S, Poyet G, Labidi-Galy SI, Goddard-Leon S, Durand I, Le Mercier I, Bajard A, Bachelot T, Puisieux A, Puisieux I, Blay JY, Ménétrier-Caux C, Caux C, Bendriss-Vermare N.

Cancer Res. 2012 Oct 15;72(20):5188-97. doi: 10.1158/0008-5472.CAN-11-3468. Epub 2012 Jul 25.

11.

Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis.

Labidi-Galy SI, Treilleux I, Goddard-Leon S, Combes JD, Blay JY, Ray-Coquard I, Caux C, Bendriss-Vermare N.

Oncoimmunology. 2012 May 1;1(3):380-382.

12.

First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.

Peron J, Tredan O, Ray-Coquard I, Bachelot T, Labidi Galy SI, Favier B, Treilleux I, Guastalla JP.

Bull Cancer. 2012 Feb 1;99(2):E18-25. doi: 10.1684/bdc.2011.1537.

13.

Therapeutic pipeline for soft-tissue sarcoma.

Cassier PA, Labidi-Galy SI, Heudel P, Dutour A, Méeus P, Chelghoum M, Alberti L, Ray-Coquard I, Blay JY.

Expert Opin Pharmacother. 2011 Nov;12(16):2479-91. doi: 10.1517/14656566.2011.604633. Epub 2011 Sep 13. Review.

PMID:
21913865
14.

Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer.

Labidi-Galy SI, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A, Combes JD, Faget J, Mithieux F, Cassignol A, Tredan O, Durand I, Ménétrier-Caux C, Caux C, Blay JY, Ray-Coquard I, Bendriss-Vermare N.

Cancer Res. 2011 Aug 15;71(16):5423-34. doi: 10.1158/0008-5472.CAN-11-0367. Epub 2011 Jun 22.

15.

Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006.

Galy G, Labidi-Galy SI, Perol D, Bachelot T, Ray-Coquard I, Tredan O, Biron P, Latour JF, Blay JY, Guastalla JP, Favier B.

Breast Cancer Res Treat. 2011 Jul;128(1):187-95. doi: 10.1007/s10549-010-1311-3. Epub 2010 Dec 24.

PMID:
21184270

Supplemental Content

Loading ...
Support Center